Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$207.61M+226.72%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yongfeng Zhang
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,976
- Beta
- 0.94
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.49
Financials
Revenue
$207.61M+226.7%Net Income
$37.76MEBITDA
$71.41MFree Cash Flow
$33.36M+284.8%EPS (diluted)
$0.87Shares Outstanding (diluted)
43.38M-5.9%Operating Expenses
$48.86MCash & Debt
$230.63MReturn of Capital
$438.0KRevenue by Segment (annual)
$70.64MDividend per Share
$0.30Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $719.89M | $98.09M | $2.10 |
| 2024 | $731.97M | $159.52M | $3.29 |
| 2023 | $644.39M | $137.54M | $2.85 |
| 2022 | $498.99M | $91.39M | $1.88 |
| 2021 | $437.77M | $62.12M | $1.30 |
| 2020 | $349.85M | $1.40M | $0.03 |
| 2019 | $322.36M | $48.94M | $1.04 |
| 2018 | $294.67M | $-5.74M | $-0.12 |
| 2017 | $240.18M | $4.51M | $0.10 |
| 2016 | $255.16M | $10.53M | $0.23 |
| 2015 | $251.52M | $-2.79M | $-0.06 |
| 2014 | $210.46M | $-10.70M | $-0.25 |
| 2013 | $229.68M | $11.86M | $1.48 |
| 2012 | $204.32M | $18.09M | $2.26 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AMPH's reported EPS growth of -0.6% a year over 13 years.
- EPS in 5 years
- $2.04
- Implied price
- $26.47
- Return from $28.89
- -1.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $13.16 — -54.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -10.6% | -17.9% | -14.5% | -11.6% | -9.0% | -6.7% |
| -5.6% | -13.3% | -9.7% | -6.7% | -4.0% | -1.5% |
| -0.6% | -8.7% | -5.0% | -1.7% | 1.1% | 3.7% |
| 4.4% | -4.1% | -0.2% | 3.2% | 6.2% | 8.9% |
| 9.4% | 0.5% | 4.6% | 8.2% | 11.3% | 14.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+11.11%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·16d ago·Neutral
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Naoki Martin - Piper Sandler & Co., Research Division Yuchen Ding - Jefferi…
View source ↗ - Newszacks.com·17d ago·Neutral
Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
Amphastar Pharmaceuticals Q3 Earnings Call Highlights Amphastar Pharmaceuticals NASDAQ: AMPH reported record third-quarter revenue of $207.6 million, up 8% from a year earlier, as sales of BAQSIMI and Primatene MIST and contributions from newer products offset manufacturing disruptions and lower pricing on some established medicines.
View source ↗ - Newszacks.com·17d ago·Positive
Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.93 per share a year ago.
View source ↗ - Newszacks.com·24d ago·Neutral
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsprnewswire.com·24d ago·Neutral
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026 RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026, after the market closes on Thursday, November 5, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.
View source ↗ - Newszacks.com·47d ago·Positive
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
View source ↗ - Newsprnewswire.com·82d ago·Neutral
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
View source ↗ - Newszacks.com·87d ago·Neutral
3 Generic Drug Stocks to Watch Amid Improving Industry Trends The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
View source ↗ - Newszacks.com·100d ago·Neutral
New Strong Sell Stocks for August 14th AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.79 per share
Typical surprise +19.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$1.14 vs $0.86beat
- Thu, Aug 6$0.91 vs $0.62beat
- Thu, May 7$0.42 vs $0.70miss
- Thu, Feb 26$0.73 vs $0.90miss
- Thu, Nov 6$0.93 vs $0.77beat
- Thu, Aug 7$0.85 vs $0.71beat
Estimates and results for AMPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMPH officers and directors.
- Bought
- —
- Sold
- $2.9m
0 trades
19 trades
- Peters William Jsold
- Peters William Jsold
- Peters William Jsold
- Peters William Jsold
- Zhou Rongsold
- Zhou Rongsold
- Prins Richard Ksold
- Peters William Jsold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AMPH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
